טוען...
Do companies in the pharmaceutical supply chain earn excess returns?
Rising drug spending has led to increased calls to curtail drug costs. However, it is unclear where to target policy solutions. We estimated excess returns (the extent to which a firm’s profits are higher than expected given the risk associated with their investments) for manufacturers and middlemen...
שמור ב:
| הוצא לאור ב: | Int J Health Econ Manag |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer US
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7780918/ https://ncbi.nlm.nih.gov/pubmed/33394339 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10754-020-09291-1 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|